课题基金 / 基金详情

项目摘要

项目成果

Harry P. Selker的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Applying for our second CTSA, Tufts Clinical and Translational Science Institute (CTSl) remains avidly committed to involving the full spectrum of clinical ahd translational research (CTR) to meet the pnsmise of biomedical science, not only bench to bedside (T1") translation, crucial to having health impact, translation into effective clinical practice ("T2"), care delivery and public health ("TS"), and health policy ('T4"). In 2008 we started Tufts CTSl building on prior CTR resources, services, and educational programs, we purposely selected partners that would leverage and complement each other's special assets. Our 38 strategically- chosen partners Include 12 Tufts University schools/research centers, ten Tufts hospitals, three academic institutions (Brandeis University, Northeastern University, RAND Corporation), eight community-based organizations, and five industry partners, an outstanding and synergistic resources, opportunities, and education across the T1-T4 spectrum. Described in our application's four sections are four aims that build on this platform: AIM 1: Strengthen Tufts CTSl overall by: 1) organizing and leading its partners in their commitment to this shared home for CTR; 2) expanding efficient access for all partners to a full spectrum of high-quality resources in a way that promotes collaborative CTR across disciplines and institutionsjS) advancing the field of CTR through local and national leadership and development of novel methods;4) providing innovative and tai^eted education and training across the T1-4 spectmm. (Section I) AIM 2: Operationalize and implement the CTR home and its infra- stnjcture, sen/ices and programs, including its central office personnel, administrative and financial management systems, committees, and other necessary structures. (Section II) AIM 3: Sustain and grow innovative resources, services, and policies that support and promote collaborative, cross-disciplinary, full-spectrum translational research. (Section III) AIM 4: Develop and broaden the CTR workforce through education and training across the T1-T4 spectrum, with a specific focus on addressing translational gaps between bench to bedside and from bedside to widespread impact on health. (Section IV) RELEVANCE (See Instmctions): Tufts Clinical and Translational Science Institute uses the entire spectrum of clinical and translational research (CTR) to help meet the promise and the public's needs of biomedical science.This includes bench "to bedside ("Tl") translation and crucially for having health impact, translation into effective clinical practice ("T2"), care delivery and public health ("TS-), and health policy (�T4").
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)
  • 批准号:
    10844980
  • 项目类别:
  • 资助金额:
    $97.51万
  • 财政年份:
    2023
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    10622002
  • 项目类别:
  • 资助金额:
    $1139.42万
  • 财政年份:
    2023
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    9816143
  • 项目类别:
  • 资助金额:
    $13.45万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    10412102
  • 项目类别:
  • 资助金额:
    $966.99万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data